


EXPRESS MAIL CERTIFICATION UNDER 37 CFR 1.10

"Express Mail" label number: EV713319738US

Date of deposit 2/21/2006

I hereby certify that the paper(s) identified above, and any document(s) referred to as attached hereto, is being deposited with the United States Postal Service on the date indicated in an envelope as "Express Mail Post Office to Addressee" and is addressed: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia, 22313-1450.


Christine Kotran

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Michael Horstmann, et al.

Serial No. :

Filing Date : Herewith

Examiner :

Group Art Unit:

Title : TRANSDERMAL PHARMACEUTICAL PREPARATION
CONTAINING ACTIVE SUBSTANCE COMBINATIONS,
FOR TREATING PARKINSON'S DISEASE
(per preliminary amendment)

Attorney File : RO4150US (#90568)

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97**

Mail Stop PCT
Commissioner for Patents
P O Box 1450
Alexandria, Virginia, 22313-1450

Dear Sir,

Under the provision of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant would like to call the Examiner's attention to the references listed on the attached Form PTO-1449. Copies of any U.S. patent or published application references are not enclosed. Copies of the indicated non-U.S. patent references and non-patent references cited in the International Search Report mailed December 22, 2004 in the prior international application PCT/EP04/009136 are not enclosed. Copies of all other references are enclosed herewith.

In accordance with 37 C.R.F. 1.97(b)(1), and as this Information Disclosure Statement is being filed with the application, the Statement is submitted before the

2005


issuance of a first Official Action on this case.

In accordance with 37 C.F.R. 1.97(g) and 37C.F.R.1.97(h), filing of this Information disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 34 C.F.R. 1.56(b).

The Examiner is requested to make the attached references of record and to consider these references along with such other references deemed pertinent as a result of the Examiner's own independent search and examination.

Respectfully submitted,

Date: February 21, 2006



D. Peter Hochberg
Reg. No. 24,603

D. Peter Hochberg Co., L.P.A.
1940 E. 6th Street - 6th Floor
Cleveland, OH 44114-2294
(216) 771-3800
DPH/sfm

Examiner Initial	Document Number	Date	Country	Translation (Yes/No)
_____	DE 3710966	12/3/87	Germany	No *
_____	EP-B-0 404807	6/30/93	EPO	No

_____	EP-A-1 256339	10/15/2003	EPO	No
_____	FR 2788982	8/4/2000	France	No *
_____	WO 89/09051	10/5/89	WO	No *
_____	WO 02/47666	6/20/2002	WO	No *

Other Prior Art (Inc. Author, Title, Date, Pertinent Pages, Etc)

Examiner
Initial

Document

_____	Schneider, E.; "Kominierte Therapien;" <u>Neuro-Psychopharmaka</u> ; Vol. 5: Parkinsonmittel und Nootropika, pp. 131-133; ed. P. Riederer, et al., Springer Verlag, Vienna (1992)
_____	Sudo, et al.; "Transdermal Absorption of L-dopa from Hydrogel in Rats; <u>Eur. J. Pharm. Sci.</u> ; 7 (1998), pp. 67-71
_____	Reiderer, P., et al.; "Neuro-Psychopharmaka, Bd 5;" (1992), Springer Verlag, Wien *
_____	Mucke, H.A.M.; "Rotigotine Schwarz Pharma;" <u>Idrugs</u> , Current Drugs Ltd., GB; Vol. 6, No. 9 (2003), pp. 894-899 *
_____	Tuite, P., et al.; "Recent Developments in the Pharmacological Treatment of Parkinson's Disease;" <u>Expert Opinion on Investigational Drugs</u> , Ashley Publications Ltd., London, GB, Vol. 12, No. 8; August 1, 2003; pp. 1335-1352 *
_____	Abramsky, O., et al.; "Combined Treatment of Parkinsonian Tremor with Propranolol and Levodopa;" <u>Journam of The Neurological Sciences</u> ; Dec. 1971; Vol. 14, No. 4; pp. 491-494 *
_____	Charles, P.D., et al.; "Classification of Tremor and Update on Treatment;" <u>American Family Physician, American Academy of Family Physicians</u> (U.S.); Vol. 59, No. 6; March 15, 1999; pp. 1565-1572 *
_____	Iravani, Mahmoud, M., et al.; "3,4-Methylenedioxymethamphetamine (Ecstasy) Inhibits Dyskinesia Expression and Normalized Motor Activity in 1-methyl-4phenyl-1,2,3,6 tetrahydropyridine-treated primates;" <u>Journal of Neuroscience</u> ; Vol. 23, No. 27; October 8, 2003; pp. 9107-9115 *

Examiner

Date Considered:

967568943

1AP20100111 11:21:33 2006
3

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant

* Denotes reference cited in International Search Report